Abstract
Hemoglobin, the protein responsible for the red color of blood plays a very important part in ‘life’- it transports oxygen, without which humans cannot survive. The idea of using purified Hemoglobin as a possible universal substitute for red blood cells has been around for almost a century. Hemoglobin formulations have important therapeutic applications, especially in case of trauma and war when requirements for blood may be very large. Manufacture of hemoglobin for use as a biopharmaceutical poses practical challenges, owing to dependence on human expired blood and fragility of the protein molecule. Biotechnology can play a critical role in breaking these barriers, by not only ensuring recombinant production of hemoglobin, but also enhancing stability of the molecule. The present article, based on a review of patents and available literature gives an insight into the IPR and technological issues involved in the commercial production of this ‘life-saving’ protein. There are more than 250 patents worldwide related to hemoglobin formulation, crosslinking and determination.
Keywords: Hemoglobin, haemoglobin, biopharmaceutical recombinant formulation, cross-linking, polymerization, blood substitute, recombinant hemoglobin, patents
Recent Patents on Biotechnology
Title: IPR and Technological Issues Regarding a Biopharmaceutical Formulation -Hemoglobin
Volume: 2 Issue: 1
Author(s): Parikshit Bansal, Chandrashekhar Honrao and Uttam C. Banerjee
Affiliation:
Keywords: Hemoglobin, haemoglobin, biopharmaceutical recombinant formulation, cross-linking, polymerization, blood substitute, recombinant hemoglobin, patents
Abstract: Hemoglobin, the protein responsible for the red color of blood plays a very important part in ‘life’- it transports oxygen, without which humans cannot survive. The idea of using purified Hemoglobin as a possible universal substitute for red blood cells has been around for almost a century. Hemoglobin formulations have important therapeutic applications, especially in case of trauma and war when requirements for blood may be very large. Manufacture of hemoglobin for use as a biopharmaceutical poses practical challenges, owing to dependence on human expired blood and fragility of the protein molecule. Biotechnology can play a critical role in breaking these barriers, by not only ensuring recombinant production of hemoglobin, but also enhancing stability of the molecule. The present article, based on a review of patents and available literature gives an insight into the IPR and technological issues involved in the commercial production of this ‘life-saving’ protein. There are more than 250 patents worldwide related to hemoglobin formulation, crosslinking and determination.
Export Options
About this article
Cite this article as:
Bansal Parikshit, Honrao Chandrashekhar and Banerjee C. Uttam, IPR and Technological Issues Regarding a Biopharmaceutical Formulation -Hemoglobin, Recent Patents on Biotechnology 2008; 2 (1) . https://dx.doi.org/10.2174/187220808783330901
DOI https://dx.doi.org/10.2174/187220808783330901 |
Print ISSN 1872-2083 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-4012 |
Call for Papers in Thematic Issues
Advancements in Plant Genetics and Genomics
This thematic issue will highlight cutting-edge innovations and recent patents across the breadth of plant genetics and genomics. Key topics will include advanced breeding techniques, omics-based approaches, gene editing, trait discovery, and translational applications for crop improvement. Renowned researchers from leading institutions worldwide will provide state-of-the-art insights and future perspectives ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
FTY720 (Fingolimod) Ameliorates Brain Injury through Multiple Mechanisms and is a Strong Candidate for Stroke Treatment
Current Medicinal Chemistry Ischemia-Reperfusion Injury of the Cochlea: Pharmacological Strategies for Cochlear Protection and Implications of Glutamate and Reactive Oxygen Species
Current Neuropharmacology The Tree of Sirtuins and the Garden of Cardiovascular Youth
Current Vascular Pharmacology The CX3C-Chemokine Fractalkine in Kidney Diseases
Mini-Reviews in Medicinal Chemistry Atrial Fibrillation in Patients Undergoing Surgical Revascularization: An Update on Pharmacologic Prophylaxis
Cardiovascular & Hematological Agents in Medicinal Chemistry Adrenomedullin: A Tumor Progression Factor via Angiogenic Control
Current Cancer Drug Targets Evaluation of Gene and Cell-Based Therapies for Cardiac Regeneration
Current Stem Cell Research & Therapy Apoptosis and Acute Brain Ischemia in Ischemic Stroke
Current Vascular Pharmacology Embolic Protection Devices in Saphenous Vein Graft and Native Vessel Percutaneous Intervention: A Review
Current Cardiology Reviews Phytochemistry and Pharmacological Update on Tetraterpenoids
The Natural Products Journal Perspectives on Medicinal Properties of Benzoquinone Compounds
Mini-Reviews in Medicinal Chemistry Dynorphins in Development and Disease: Implications for Cardiovascular Disease
Current Molecular Medicine Update on Fondaparinux: Role in Management of Thromboembolic and Acute Coronary Events
Cardiovascular & Hematological Agents in Medicinal Chemistry Biocompatibility and Biotolerability Assessment of Microspheres Using a Whole Blood Model
Micro and Nanosystems Therapeutic Targeting of Toll-Like Receptors in Gastrointestinal Inflammation
Current Pharmaceutical Design Hepatic Diseases Related to Triglyceride Metabolism
Mini-Reviews in Medicinal Chemistry The Potential Role of Sirtuins Regarding the Effects of Exercise on Aging- Related Diseases
Current Aging Science Modulation of Cardiovascular Remodeling with Statins: Fact or Fiction?
Current Vascular Pharmacology The Role of Peptidyl Prolyl Isomerases in Aging and Vascular Diseases
Current Molecular Pharmacology DNAzyme Delivery Approaches in Biological Settings
Current Medicinal Chemistry